The observed reductions in both total and percent cystatin C in ALS patients relative to DC may reflect actual differences in clinical cystatin C levels, but a total study enrollment of 1020 and 675 patients (for total and percent cystatin C, respectively) would be required to confirm statistical significance with 80% power and 95% confidence. This evidence concerns the gene CST3 and amyotrophic lateral sclerosis.